SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and financial results for the three months ended March 31, 2022.
"I would like to highlight the fact that our business units are steadily growing based on the first quarter reported results and the evaluation portion of our Phase 1 clinical trial is progressing successfully as well." stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO. " stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO.
Q1 2022 Financial Highlights:
- Consolidated revenue for the first quarter of 2022 was $2.02 million, an increase of 22% compared to the consolidated revenue of $1.66 million for the first quarter of 2021.
- Combined operating income for the quarter ended March 31, 2022, from our two wholly owned revenue generating subsidiaries was $648,000, an increase of 164% compared to $245,000 in the first quarter of 2021.
- Net loss for ISCO was $9,000 for the first quarter of 2022 compared to a net loss of $599,000 for the first quarter in 2021, a decrease of 98%.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information, please visit http://internationalstemcell.com/ or contact: [email protected]
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments and company achievements, expected clinical studies (including results and ongoing evaluation of the phase 1 clinical trial), and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share and par value data)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash | $ | 398 | $ | 171 | ||||
Accounts receivable, net | 902 | 844 | ||||||
Inventory, net | 1,322 | 1,184 | ||||||
Prepaid expenses and other current assets | 338 | 135 | ||||||
Total current assets | 2,960 | 2,334 | ||||||
Non-current inventory, net | 390 | 372 | ||||||
Property and equipment, net | 348 | 384 | ||||||
Intangible assets, net | 933 | 949 | ||||||
Operating right-of-use assets | 835 | 868 | ||||||
Deposits and other assets | 35 | 39 | ||||||
Total assets | $ | 5,501 | $ | 4,946 | ||||
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Deficit | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 635 | $ | 508 | ||||
Accrued liabilities | 505 | 404 | ||||||
Operating lease liabilities, current | 196 | 179 | ||||||
Advances | 250 | 250 | ||||||
Related party note payable | 3,225 | 2,943 | ||||||
Total current liabilities | 4,811 | 4,284 | ||||||
Operating lease liabilities, net of current portion | 896 | 950 | ||||||
Total liabilities | 5,707 | 5,234 | ||||||
Commitments and contingencies (Note 8) | ||||||||
Series D redeemable convertible preferred stock, $0.001 par value; 50 shares authorized; 43 shares issued and outstanding; liquidation preference of $4,300 at March 31, 2022 and December 31, 2021, respectively | 4,300 | 4,300 | ||||||
Stockholders' deficit: | ||||||||
Non-redeemable convertible preferred stock, $0.001 par value; 10,004,310 shares authorized; 5,254,310 shares issued and outstanding; liquidation preference of $9,770 and $9,766 at March 31, 2022 and December 31, 2021, respectively | 5 | 5 | ||||||
Common stock, $0.001 par value; 120,000,000 shares authorized; 8,004,389 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 8 | 8 | ||||||
Additional paid-in capital | 105,504 | 105,413 | ||||||
Accumulated deficit | (110,023 | ) | (110,014 | ) | ||||
Total stockholders' deficit | (4,506 | ) | (4,588 | ) | ||||
Total liabilities, redeemable convertible preferred stock and stockholders' deficit | $ | 5,501 | $ | 4,946 | ||||
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
Product sales, net | $ | 2,020 | $ | 1,658 | ||||
Operating expenses: | ||||||||
Cost of sales | 725 | 615 | ||||||
Research and development | 137 | 215 | ||||||
Selling and marketing | 301 | 347 | ||||||
General and administrative | 832 | 1,048 | ||||||
Total operating expenses | 1,995 | 2,225 | ||||||
Income (loss) from operations | 25 | (567 | ) | |||||
Other expense: | ||||||||
Interest expense - related party | (34 | ) | (32 | ) | ||||
Total other expense | (34 | ) | (32 | ) | ||||
Net loss | $ | (9 | ) | $ | (599 | ) | ||
Net loss per common share, basic and diluted | $ | (0.00 | ) | $ | (0.08 | ) | ||
Weighted-average common shares used to compute net loss per share, basic and diluted | 8,004 | 7,539 | ||||||
Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: [email protected]
SOURCE: International Stem Cell Corporation